{
    "nct_id": "NCT05702229",
    "official_title": "An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",
    "inclusion_criteria": "* 18 years or older at the time of signing the ICF.\n* Body weight > 35 kg.\n* Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.\n* Has measurable target disease assessed by the Investigator based on RECIST 1.1.\n* ECOG PS zero or one.\n* Life expectancy of at least 12 weeks.\n* Adequate organ and bone marrow function.\n* Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.\n* Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.\n* Participants with ascites which cannot be controlled with appropriate interventions.\n* Active infectious diseases, including tuberculosis, HIV infection, or hepatitis A/B/C.\n* Uncontrolled intercurrent illness.\n* Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.\n* History of another primary malignancy.\n* Previous treatment with an immune-oncology agent.\n* Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).",
    "miscellaneous_criteria": ""
}